(Total Views: 485)
Posted On: 06/12/2018 4:24:42 PM
Post# of 30067
.jpg)
Re: All Aboard #26842
I got you fam:
GC lookin scruffy, but fit, and had a good energy and better projection of competence (he hasn't always had that from my point of view)
in process of completing scientific adviser recruitment for MANF Tx (I think)
no new specifics on why Reg A+. As a re-cap there are mechanisms that are useful to us
Elto spinoff via IPO/merge will allow us to complete recap
the arbitrage between recap value of company and value of assets makes RegA+ useful
new IP has been filed but not issued around Elto formulations for additional patent protection
new data on elto out in near future from previous studies
they have IP around elto in combo with gycovri
there were no clinical dev scales for alzheimers aggression back in the day
he did a better job of ELI5 for a less experienced biotech crowd
multi-dose 8 week study for elto just to figure best dosing then straight into phase 3
original amarantus model to elto priced at $5000. But gycovri prices and gets 5x as much because its a significant need
SEC filing with full $316M valuation coming shortly
Cutanogen cost the company approx $12M in all
In process of moving Cutanogen away from Lonza to a new group(Lonza=greedy poisonous fucks imo)
Dr. Ahrenholz is officially consulting for us now to get through FDA
significant progress being made on hair follicle and melanocyte research
working with shriners hospital and Dr. Kagan on RPDD application
once the parent company is stabilized, the potential for DOD etc other funding sources may return
no new info on lympro 2.0 data but they're in the process of doing the paperwork on the option
MANF-orphan opthalmagic initial
AP restructuring still in progress. Announcement within next several weeks. Overtime they'll take out the overhang
We may uplist sooner rather than later based on sub success
He recieved zero questions. Couldn't see the whole room, but audience seemed like it probably wasn't too big, maybe 10 clappers
Also they'll have replay by 430 or 5 eastern
GC lookin scruffy, but fit, and had a good energy and better projection of competence (he hasn't always had that from my point of view)
in process of completing scientific adviser recruitment for MANF Tx (I think)
no new specifics on why Reg A+. As a re-cap there are mechanisms that are useful to us
Elto spinoff via IPO/merge will allow us to complete recap
the arbitrage between recap value of company and value of assets makes RegA+ useful
new IP has been filed but not issued around Elto formulations for additional patent protection
new data on elto out in near future from previous studies
they have IP around elto in combo with gycovri
there were no clinical dev scales for alzheimers aggression back in the day
he did a better job of ELI5 for a less experienced biotech crowd
multi-dose 8 week study for elto just to figure best dosing then straight into phase 3
original amarantus model to elto priced at $5000. But gycovri prices and gets 5x as much because its a significant need
SEC filing with full $316M valuation coming shortly
Cutanogen cost the company approx $12M in all
In process of moving Cutanogen away from Lonza to a new group(Lonza=greedy poisonous fucks imo)
Dr. Ahrenholz is officially consulting for us now to get through FDA
significant progress being made on hair follicle and melanocyte research
working with shriners hospital and Dr. Kagan on RPDD application
once the parent company is stabilized, the potential for DOD etc other funding sources may return
no new info on lympro 2.0 data but they're in the process of doing the paperwork on the option
MANF-orphan opthalmagic initial
AP restructuring still in progress. Announcement within next several weeks. Overtime they'll take out the overhang
We may uplist sooner rather than later based on sub success
He recieved zero questions. Couldn't see the whole room, but audience seemed like it probably wasn't too big, maybe 10 clappers
Also they'll have replay by 430 or 5 eastern
(7)
(0)
